Morgan Stanley Adjusts Synopsys Price Target to $574 From $500

Morgan Stanley raised its price target for Synopsys to $574 from $500, forecasting fiscal 2027 EPS of $19.12. The firm believes Synopsys' AI story isn't fully priced in, but a re-rating depends on execution and proof of usage revenue growth. Investors will watch for metrics like customer retention and contracted backlog.

Morgan Stanley argues Synopsys is undervalued, citing overlooked AI revenue potential. The firm raised its price target to $574 from $500 and maintains an Overweight rating. Synopsys' stock has declined 9.07% year-to-date.

Morgan Stanley raised Synopsys' (SNPS) price target to $574 from $550, citing AI growth potential. SNPS shares dipped 0.8% premarket. GF Value™ estimates intrinsic value at $661.95, 32.8% above current price. SNPS has a GF Score™ of 93/100, reflecting strong growth and profitability. The stock's P/E ratio is 78.61x, below its 5-year median of 59.07x.

Morgan Stanley raised its price target for Synopsys (SNPS) to $574, citing AI-driven expansion. The firm believes Synopsys' valuation discount is unwarranted. Shares fell 0.8% in premarket trading.

Synopsys (SNPS) saw its price target raised by Needham following its investor day. The firm reportedly presented positively, with a notable announcement involving GPT-Synopsys, though details were not provided in the summary. This update may influence investor perceptions and trading activity.

Needham raised its price target on Synopsys to $620 from $580. The company's stock is currently trading at $509.99, with a 5-day change of +2.46% and a year-to-date change of +8.57%. Synopsys is also working to comply with US export rules using Chinese models.